Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-017-03069-1 http://scihub22266oqcxt.onion/10.1038/s41598-017-03069-1 C5460274!5460274 !28588208     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28588208 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Sci+Rep 2017 ; 7 (1 ): 2871 Nephropedia Template TP {{tp|p=28588208 |t=2017. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance |pdf=|usr=}}{{28588208 }} gab.com Text Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=28588208 #FOAvip Proton pump inhibitor (PPI)-induced inhibition of dimethylarginine dimethylaminohydrolase 1 (DDAH1), with consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), might explain the increased cardiovascular risk with PPI use. However, uncertainty exists regarding whether clinical PPI concentrations significantly inhibit DDAH1 under linear initial rate conditions, and whether PPI-induced DDAH1 inhibition significantly increases ADMA in humans. DDAH1 inhibition by esomeprazole, omeprazole, pantoprazole, lansoprazole and rabeprazole was determined by quantifying DDAH1-mediated L-citrulline formation in vitro. Plasma ADMA was measured in PPI users (n?=?134) and non-users (n?=?489) in the Hunter Community Study (HCS). At clinical PPI concentrations (0.1-10??mol/L), DDAH1 retained >80% activity vs. baseline. A significant, reversible, time-dependent inhibition was observed with lansoprazole (66% activity at 240?min, P?=?0.034) and rabeprazole (25% activity at 240?min, P?<?0.001). In regression analysis, PPI use was not associated with ADMA in HCS participants (beta 0.012, 95% CI -0.001 to 0.025, P?=?0.077). Furthermore, there were no differences in ADMA between specific PPIs (P?=?0.748). At clinical concentrations, PPIs are weak, reversible, DDAH1 inhibitors in vitro. The lack of significant associations between PPIs and ADMA in HCS participants questions the significance of DDAH1 inhibition as a mechanism explaining the increased cardiovascular risk reported with PPI use. Twit Text FOAVip Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=28588208 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28588208 #FOAvip English Wikipedia <ref>{{Cite pmid|28588208 }}</ref> Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance #MMPMID28588208 Tommasi S ; Elliot DJ ; Hulin JA ; Lewis BC ; McEvoy M ; Mangoni AA Sci Rep 2017[Jun]; 7 (1 ): 2871 PMID28588208 show ga Proton pump inhibitor (PPI)-induced inhibition of dimethylarginine dimethylaminohydrolase 1 (DDAH1), with consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), might explain the increased cardiovascular risk with PPI use. However, uncertainty exists regarding whether clinical PPI concentrations significantly inhibit DDAH1 under linear initial rate conditions, and whether PPI-induced DDAH1 inhibition significantly increases ADMA in humans. DDAH1 inhibition by esomeprazole, omeprazole, pantoprazole, lansoprazole and rabeprazole was determined by quantifying DDAH1-mediated L-citrulline formation in vitro. Plasma ADMA was measured in PPI users (n?=?134) and non-users (n?=?489) in the Hunter Community Study (HCS). At clinical PPI concentrations (0.1-10??mol/L), DDAH1 retained >80% activity vs. baseline. A significant, reversible, time-dependent inhibition was observed with lansoprazole (66% activity at 240?min, P?=?0.034) and rabeprazole (25% activity at 240?min, P? |Aged [MESH] |Aged, 80 and over [MESH] |Amidohydrolases/*antagonists & inhibitors [MESH] |Arginine/*analogs & derivatives/blood/metabolism [MESH] |Australia/epidemiology [MESH] |Biomarkers [MESH] |Cardiovascular Diseases/blood/epidemiology/*etiology/*metabolism [MESH] |Chromatography, High Pressure Liquid [MESH] |Female [MESH] |Humans [MESH] |Male [MESH] |Mass Spectrometry [MESH] |Middle Aged [MESH] |Proton Pump Inhibitors/*adverse effects/pharmacology [MESH]Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton p(epmc).pdf DeepDyve Pubget Overpricing